`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`Celltrion, Inc.
`Petitioner,
`
`v.
`
`Genentech, Inc.
`Patent Owner
`
`Patent No. 6,407,213
`
`
`
`
`
`Inter Partes Review No. IPR2017-01373
`
`
`PETITIONER’S FOURTH UPDATED MANDATORY NOTICES
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Celltrion, Inc. hereby updates its Mandatory Notices pursuant to 37 C.F.R. §
`
`42.8(a)(3) to add related matters and counsel and to update service information.
`
`A. REAL PARTIES-IN-INTEREST (37 C.F.R. § 42.8(b)(1)) (No
`Change)
`
`The real parties-in-interest are Celltrion, Inc. (“Petitioner”), Celltrion
`
`
`
`Healthcare Co. Ltd. (“CTHC”), and Teva Pharmaceuticals International GmbH
`
`(“Teva”).
`
`
`
`B. RELATED MATTERS (37 C.F.R. § 42.8(b)(2)) (Updated)
`
`Patent No. 6,407,213 (“the ’213 patent”) is related to the following patents:
`
`U.S. Pat. Nos. 6,639,055, 6,800,738, and 6,719,971 (all expired for maintenance fee
`
`non-payment), and U.S. Pat. No. 8,075,890.
`
`Petitioner additionally challenged claims of the ’213 patent in IPR2017-
`
`01374, which was instituted. Pfizer Inc. challenged the ’213 patent in IPR2017-
`
`01488 and IPR2017-01489, which were both instituted. Boehringer Ingelheim
`
`Pharmaceuticals, Inc. challenged the ’213 patent in IPR2017-02031 and
`
`IPR2017-02032, which were both instituted. Samsung Bioepis Co., Ltd. challenged
`
`the ’213 patent in IPR2017-02139 and IPR2017-02140. Those proceedings were
`
`instituted and joined with IPR2017-01488 and IPR2017-01489, respectively.
`
`The ’213 patent is at issue in the following litigations: Amgen Inc v.
`
`Genentech, Inc. et al, No. 17-cv-07349 (C.D. Cal.); Genentech, Inc. et al v.
`
`Amgen Inc., No. 17-cv-01407 (D. Del.); Genentech, Inc. et al v. Amgen Inc., No.
`
`
`
`2
`
`
`
`
`
`17-cv-01471 (D. Del.); Genentech, Inc. v. Pfizer, Inc., No. 17-cv-01672 (D.
`
`Del.); Genentech, Inc. et al v. Celltrion, Inc. et al., No. 18-cv-00095 (D.Del.);
`
`and Celltrion, Inc. et al v. Genentech, Inc. et al, No. 18-cv-00274 (N.D.Cal.).
`
`C.
`
`IDENTIFICATION OF COUNSEL AND SERVICE
`INFORMATION (37 C.F.R. § 42.8(b)(3) & (4)) ( Updated)
`Lead counsel is Cynthia Lambert Hardman, Reg. No. 53,179
`
`(chardman@goodwinlaw.com), and backup counsel are Elizabeth J. Holland (Reg.
`
`No. 47,657) (eholland@goodwinlaw.com), and Robert V. Cerwinski (admitted
`
`hac vice) (rcerwinski@goodwinlaw.com) ). Counsel are with Goodwin Procter
`
`LLP, 620 Eighth Avenue, New York, NY, 10018, Tel. (212) 813- 8800, Fax (212)
`
`355-3333. Please direct all correspondence to counsel using this contact
`
`information. Petitioner consents to electronic mail service:
`
`chardman@goodwinlaw.com, eholland@goodwinlaw.com, and
`
`rcerwinski@goodwinlaw.com.
`
`Dated: April 20, 2018
`
`By: /Cynthia Lambert Hardman/
`Cynthia Lambert Hardman (Reg. No. 53,179)
`Elizabeth J. Holland(Reg. No. 47,657)
`Robert V. Cerwinski (admitted pro hac vice)
`GOODWIN PROCTER LLP
`The New York Times Building
`620 Eighth Avenue
`New York, NY 10018
`(212) 813-8800 (telephone)
`(212) 355-3333 (facsimile)
`
`
`
`Counsel for Petitioner
`
`
`3
`
`
`
`
`
`
`
`CERTIFICATE OF SERVICE
`Pursuant to 37 C.F.R. § 42.6(e), I certify that on this 20th day of April, 2018,
`
`I caused a copy of this PETITIONER’S FOURTH UPDATED MANDATORY
`
`NOTICES to be served by email on the lead and back up counsel for Patent Owners
`
`at:
`
`
`
`
`
`
`
`David Cavanaugh (David.Cavanaugh@wilmerhale.com)
`
`Lauren V. Blakely (lauren.blakely@wilmerhale.com)
`
`Robert Gunther (Robert.Gunther@wilmerhale.com)
`
`Adam Brausa (abrausa@durietangri.com)
`
`Daralyn Durie (ddurie@durietangri.com)
`
`Andrew Danford (Andrew.Danford@wilmerhale.com)
`
`Lisa Pirozzolo (Lisa.Pirozzolo@wilmerhale.com)
`
`Kevin Prussia (Kevin.Prussia@wilmerhale.com)
`
`/Cynthia Lambert Hardman/
`
`Cynthia Lambert Hardman (Reg. No.
`53,179)
`GOODWIN PROCTER LLP
`The New York Times Building
`620 Eighth Avenue
`New York, NY 10018
`(212) 813-8800 (telephone)
`(212) 355-3333 (facsimile)
`
`
`
`